

CITATION REPORT

List of articles citing

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

DOI: 10.1177/1352458505070618

Multiple Sclerosis Journal, 2006, 12, 639-45.

Source: <https://exaly.com/paper-pdf/39531200/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
229	The development of Sativex [®] – a natural cannabis-based medicine. 2005 , 231-263		16
228	Cannabinoids in MS--are we any closer to knowing how best to use them?. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 523-5	5	5
227	Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. 2007 , 31, 477-85		65
226	The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. 2007 , 14, 475-83		49
225	Cannabinoids. 2007 , 21, 19-28		3
224	Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. 2007 , 7, 1157-63		15
223	Cannabinoïdes et douleur. 2007 , 8, 218-226		1
222	Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. 2007 , 56, 428-42		46
221	History of cannabis and its preparations in saga, science, and sobriquet. 2007 , 4, 1614-48		286
220	Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. 2007 , 4, 1729-43		155
219	The toxicology of cannabis and cannabis prohibition. 2007 , 4, 1744-69		58
218	Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. 2007 , 1163, 318-27		63
217	Improving containment strategies in biopharming. 2007 , 5, 555-69		65
216	The complex etiology of multiple sclerosis. 2007 , 74, 1321-9		7
215	The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Inflammopharmacology</i> , 2007 , 15, 183-7	5.1	7
214	Cannabinoid-based medicines for neurological disorders--clinical evidence. 2007 , 36, 129-36		18
213	Cannabinoids and multiple sclerosis. 2007 , 36, 45-59		64

212	Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue. 2007 , 36, 36-44	4
211	Alternative therapies for overactive bladder: Cannabis and urge incontinence. 2008 , 3, 224-229	
210	Seizures in multiple sclerosis. 2008 , 49, 948-53	87
209	Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?. 2008 , 273, 103-7	16
208	Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. 2008 , 9, 254-64	169
207	Current management of pain associated with multiple sclerosis. 2008 , 22, 291-324	89
206	Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. 2008 , 30, 974-85	164
205	Managing neuropathic pain with Sativex: a review of its pros and cons. 2008 , 9, 1189-95	21
204	Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 , 79, 1224-9	52
203	The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. 2008 , 283, 13320-9	124
202	Adverse effects of medical cannabinoids: a systematic review. 2008 , 178, 1669-78	219
201	Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol. 2008 , 13, 393-403	12
200	The endocannabinoid system and multiple sclerosis. 2008 , 14, 2326-36	46
199	Multiple sclerosis, cannabinoids, and cognition. 2008 , 20, 36-51	9
198	Pharmacological management of spasticity. 131-149	1
197	Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. 2008 , 109, 101-10	93
196	Cannabinoids in the management of difficult to treat pain. 2008 , 4, 245-59	162
195	Cannabinoids in chronic pain and palliative care. 2008 , 58, 267-79	8

194	Addiction and the pharmacology of cannabis: implications for medicine and the law. 2009 , 49, 1-17	5
193	Spasticity management, part 2: Choosing the right medication to suit the individual. 2009 , 5, 419-424	4
192	Cannabinoids, multiple sclerosis and neuroprotection. 2009 , 2, 645-60	11
191	Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. 2009 , 9, 59	53
190	Novedades sobre el cannabis. 2009 , 16, 204-212	
189	Systematic review and meta-analysis of cannabis treatment for chronic pain. 2009 , 10, 1353-68	137
188	Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. 2009 , 13, 472-7	34
187	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. 2009 , 23, 133-44	182
186	Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. 2009 , 32, 41-7	59
185	Prise en charge de la spasticité dans la sclérose en plaques. 2010 , 26, 167-170	1
184	Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. 2010 , 39, 167-79	350
183	The endocannabinoid system as a target for the treatment of neurodegenerative disease. 2010 , 160, 480-98	118
182	Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. 2010 , 70, 656-63	81
181	New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. 2010 , 6, 59-63	13
180	A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. 2010 , 32, 451-9	190
179	Drugs, Dreams, and Nightmares. 2010 , 5, 277-287	14
178	Role of cannabinoids in the treatment of pain and (painful) spasticity. 2010 , 70, 2409-38	63
177	Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1349-59	5 120

176	The effects of the synthetic cannabinoid receptor agonists, WIN55,212-2 and CP55,940, on salicylate-induced tinnitus in rats. 2010 , 268, 145-50		21
175	Cannabis-based medicines in multiple sclerosis--a review of clinical studies. 2010 , 215, 658-72		33
174	Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 707-14	5	121
173	Role of cannabinoids in multiple sclerosis. 2011 , 25, 187-201		79
172	A drug discovery case history of Delta-9-tetrahydrocannabinol, cannabidiol. 2011 , 6, 437-52		4
171	Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. 2011 , 57, 66-75		147
170	THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. 2011 , 11, 627-37		67
169	Sativex® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. 2011 , 11, 15-9		21
168	Neurochemical basis of cannabis addiction. 2011 , 181, 1-17		78
167	Prolonged cannabinoid exposure alters GABA(A) receptor mediated synaptic function in cultured hippocampal neurons. 2011 , 229, 264-73		17
166	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. 2011 , 18, 1122-31		276
165	Subjective and physiological effects after controlled Sativex and oral THC administration. 2011 , 89, 400-7		82
164	Abuse potential and psychoactive effects of Delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. 2011 , 10, 675-85		69
163	Cannabinoids for pain management. 2011 , 30, 125-138		10
162	Treating pain in multiple sclerosis. 2011 , 12, 2355-68		26
161	Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids. 2011 , Volume 1, 15-23		1
160	What physicians need to know about dreams and dreaming. 2012 , 18, 574-9		9
159	A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 219-28	5	110

158	Herbal Medicines for the Prevention and Treatment of Alzheimer's Disease. 2012 , 18, 57-75	62
157	The endocannabinoid system in normal and pathological brain ageing. 2012 , 367, 3326-41	85
156	Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?. 2012 , 12, 9-14	18
155	Sativex [®] in multiple sclerosis spasticity: a cost-effectiveness model. 2012 , 12, 439-41	26
154	Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. 2012 , 2012, 802649	27
153	Are cannabinoids more effective than placebo in decreasing MS-related bladder dysfunction?. 2012 , 8, 71-78	3
152	Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. 2012 , 5, 255-66	32
151	Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. 2012 , 18, 5008-14	5
150	The therapeutic potential of cannabis and cannabinoids. 2012 , 109, 495-501	176
149	Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. 2012 , 12, 3-8	18
148	Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. 2012 , 12, 1517-31	16
147	Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. 2012 , 62, 2299-308	63
146	Cost effectiveness of oromucosal cannabis-based medicine (Sativex [®]) for spasticity in multiple sclerosis. 2012 , 30, 1157-71	14
145	Medical marijuana: clearing away the smoke. 2012 , 6, 18-25	57
144	[Cannabinoids for symptomatic therapy of multiple sclerosis]. 2012 , 83, 695-704	6
143	The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. 2012 , 34, 1056-69	25
142	The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. 2012 , 1, 64-75	19
141	Phytocannabinoids as novel therapeutic agents in CNS disorders. 2012 , 133, 79-97	204

140	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. 2013 , 56, 8224-56	96
139	The effects of antitussive treatment of ACE inhibitor-induced cough on therapy compliance: a prescription sequence symmetry analysis. 2013 , 36, 435-9	18
138	A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. 2013 , 13, 15-9	22
137	Cannabinoids. 2013 , 46, 142-9	26
136	Integrative therapies for multiple sclerosis. 2013 , 59, 290-301	8
135	Role of Cannabinoids in Pain Management. 2013 , 181-197	17
134	Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report. 2013 , 6, 199-203	4
133	A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. 2013 , 14, 192-9	12
132	Evaluation of the effects of reflexology on quality of life and symptomatic relief in multiple sclerosis patients with moderate to severe disability; a pilot study. 2013 , 27, 591-8	14
131	Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. 2013 , 29, 162-71	37
130	The endocannabinoid system, cannabinoids, and pain. 2013 , 4, e0022	84
129	. 2014 ,	3
128	Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. 2014 , 14, 1243-50	10
127	The growing trend of medical marijuana. 2014 , 12, 30-38	1
126	THC:CBD spray and MS spasticity symptoms: data from latest studies. 2014 , 71 Suppl 1, 4-9	28
125	Who benefits most from THC:CBD spray? Learning from clinical experience. 2014 , 71 Suppl 1, 10-5	5
124	Therapeutic potential of cannabinoid medicines. 2014 , 6, 24-30	74
123	Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. 2014 , 82, 1083-92	125

122	Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. 2014 , 74, 563-78	50
121	Mechanisms and pharmacology of neuropathic pain in multiple sclerosis. 2014 , 20, 75-97	11
120	Cannabinoids for neuropathic pain. 2014 , 18, 451	20
119	The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. 2014 , 28, 216-25	46
118	Therapeutic Potential of Cannabinoids Perspectives for the Future. 2014 , 11, 283-311	6
117	Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. 2014 , 82, 1556-63	37 ^o
116	Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. 2014 , 33, 46-53	44
115	Cannabinoids and the brain: New hopes for new therapies. 2014 , 175-218	
114	Country break-out session highlights. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 31-7	2.8
113	Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been 2015 , 55, 885-916	102
112	Observational Safety Study of THC: CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity. 2015 , 05,	4
111	Cannabinoid CB1 Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in Rats. 2015 , 6, 60	21
110	Therapeutic potential of cannabinoids in counteracting chemotherapy-induced adverse effects: an exploratory review. 2015 , 29, 332-8	14
109	Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. 2015 , 10, 10	51
108	Endocannabinoids and epilepsy. 2015 , 125-172	4
107	Medical marijuana programs - Why might they matter for public health and why should we better understand their impacts?. 2015 , 2, 53-6	17
106	Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability. 2015 , 131, 9-16	17
105	Re-branding cannabis: the next generation of chronic pain medicine?. 2015 , 5, 13-21	20

104	Cannabinoids: is there a potential treatment role in epilepsy?. 2015 , 16, 1911-4	20
103	Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. 2015 , 15, 909-18	15
102	Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. 2015 , 15, 379-91	12
101	[A breakthrough for the treatment of spasticity in multiple sclerosis]. 2015 , 171, 327-8	1
100	Nonopioid medications for pain. 2015 , 26, 219-48	18
99	Cannabis and Endocannabinoid Signaling in Epilepsy. 2015 , 231, 285-316	49
98	Safety and Toxicology of Cannabinoids. 2015 , 12, 735-46	48
97	Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). 2015 , 16, 1233-1242	140
96	"Disease modifying nutricals" for multiple sclerosis. 2015 , 148, 85-113	34
95	Treatment of Chronic Pain by Medical Approaches. 2015 ,	
94	An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex (THC:CBD, nabiximols) oromucosal spray. 2016 , 12, 1667-1675	27
93	Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. <i>Frontiers in Pharmacology</i> , 2016 , 7, 309	5.6 67
92	Medicinal Uses of Marijuana and Cannabinoids. 2016 , 35, 378-405	33
91	Genomic and Chemical Diversity in Cannabis. 2016 , 35, 349-363	73
90	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. 2016 , 87, 944-51	63
89	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5 83
88	Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. 2016 , 10, 123-126	22
87	Effective treatment of spasticity using dronabinol in pediatric palliative care. 2016 , 20, 898-903	25

86	Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. 2016 , 56, 845-51	12
85	An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. 2016 , 17, 982-1000	48
84	Use of Cannabinoids for Spasticity and Pain Management in MS. 2016 , 18, 1	13
83	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. 2016 , 37, 613-22	9
82	Cannabinoids in the Treatment of Epilepsy. 2016 , 374, 94-5	22
81	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. 2016 , 15, 270-8	550
80	Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. 2016 , 9, 9-30	41
79	Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. 2016 , 12, 638-54	37
78	Cannabinoids, cannabinoid receptors and tinnitus. 2016 , 332, 210-216	10
77	Cannabinoids to treat spinal cord injury. 2016 , 64, 190-9	18
76	Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex): A Review in Multiple Sclerosis-Related Spasticity. 2017 , 77, 563-574	53
75	Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review. 2017 , 31, 867-889	15
74	Natural (THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB receptor. 2017 , 7, 10516	32
73	Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants. 2017 , 7, 333-343	21
72	Multiple sclerosis symptoms and spasticity management: new data. <i>Neurodegenerative Disease Management</i> , 2017 , 7, 7-11	2.8 15
71	Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. 2017 , 17, 22-31	46
70	The impact of drugs for multiple sclerosis on sleep. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 5-13	5 19
69	Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex. 2017 , 135, 442-448	12

68	The Endocannabinoid System and Human Brain Functions. 2017 , 115-186			3
67	Multiple Sclerosis. 2017 , 145-179			1
66	Cannabinoids and Their Effects on Painful Neuropathy. 2017 , 905-916			
65	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). 2017 , 12, e0180651			20
64	Cannabinoids. 2018 , 371-384			1
63	A prospective observational study of problematic oral cannabinoid use. 2018 , 235, 409-417			7
62	Practical considerations in medical cannabis administration and dosing. 2018 , 49, 12-19			261
61	Substance-related disorders: A review of prevalence and correlates among patients with chronic pain. 2018 , 87, 245-254			13
60	Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. 2018 , 7, 751-758			28
59	Cannabinoids and Pain: New Insights From Old Molecules. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1259	5.6		104
58	Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. 2018 , 58, 1139-1186			97
57	Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials. 2018 , 5,			22
56	Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. 2018 , 19, 37			84
55	Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. 2018 , 5,			11
54	The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray). 2019 , 14, e0219670			2
53	Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. 2019 , 45, 580-595			6
52	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. 2019 , 9, e024793			20
51	Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. 2019 , 18, 504-512			119

50	Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan). 2019 , 27, 264-270	5
49	Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. 2019 , 27, 383-390	10
48	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. 2020 , 91, 914-920	1
47	Does alleviate tinnitus? A review of the current literature. 2020 , 5, 1147-1155	2
46	Application of Cannabinoids in Neurosciences: Considerations and Implications. 2020 , 43, 216-231	
45	Towards Better Delivery of Cannabidiol (CBD). 2020 , 13,	31
44	Safety Considerations in Cannabinoid-Based Medicine. 2020 , 13, 1317-1333	10
43	Pharmacotherapeutic Options for Managing Pain in Multiple Sclerosis. 2020 , 34, 749-761	0
42	Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain: A Systematic Review. 2020 , 36, 302-319	8
41	Cannabis and multiple sclerosis. 2020 , 20, 849-854	9
40	The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. 2020 , 1866, 165771	16
39	The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis. 2020 , 69, 549-558	11
38	Predictors of Nabiximols (Sativex) discontinuation over long-term follow-up: a real-life study. 2020 , 267, 1737-1743	6
37	Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. 2021 , 22,	14
36	Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. 2021 , 35, 773-785	9
35	Le système de signalisation endocannabinoïde: structure, fonction, pharmacologie. 2021 , 22, 53-67	
34	Cost-effectiveness of adding Sativex [®] spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. 2021 , 22, 711-721	0
33	Use of cannabis in patients with multiple sclerosis from Argentina. 2021 , 51, 102932	2

32	Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. 2021 , 38, 887-910		1
31	Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials. 2021 , 21, 755-778		2
30	Assessing the impact of a cannabis course on pharmacy students Understanding, beliefs and preparedness regarding medical and recreational cannabis.. 2022 , 155, 50-59		
29	Cannabinoid-Based Medicines and Multiple Sclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1264, 111-129	3.6	6
28	Neue Arzneimittel 2011. 2012 , 43-126		1
27	Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis. 2019 , 265-426		2
26	Cannabis and Cannabinoids for Chronic Pain. <i>Current Rheumatology Reports</i> , 2017 , 19, 67	4.9	50
25	Misuse of, and dependence on, alcohol and other drugs. 2010 , 353-389		1
24	Toxicological properties of Δ -tetrahydrocannabinol and cannabidiol. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2020 , 71, 1-11	1.7	11
23	Cannabinoids in health and disease. <i>Dialogues in Clinical Neuroscience</i> , 2007 , 9, 413-30	5.7	131
22	Cannabinoids for the Control of multiple Sclerosis. 2008 , 375-394		
21	The Endocannabinoid System in the Cochlear Nucleus and Its Implications for Tinnitus Treatment. 2011 , 639-647		1
20	Role of Cannabinoids in Pain Management. 2015 , 179-195		
19	Zentrales Nervensystem. 2015 , 229-415		
18	Zentrales Nervensystem. 2018 , 253-445		
17	Current state of knowledge on the use of medical marijuana in some neurological diseases. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2020 , 36, 205-225	0.1	
16	Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol. <i>Cannabis and Cannabinoid Research</i> , 2021 ,	4.6	1
15	"The Two Sides of the Same Coin"-Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	2

14 Zentrales Nervensystem. **2022**, 301-510

13 Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.. *Neurodegenerative Disease Management*, **2022**, 2.8 0

12 Medicinal Cannabis and Central Nervous System Disorders.. *Frontiers in Pharmacology*, **2022**, 13, 881810 5.6 0

11 The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms. *Life*, **2022**, 12, 682 3 3

10 An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity. *Advances in Clinical Neuroscience & Rehabilitation: ACNR*, 0.3

9 Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. *Frontiers in Cellular Neuroscience*, 16, 6.1 0

8 Proposed mechanisms of cannabinoid hyperemesis syndromeHow can cannabinoid pathways both relieve and cause vomiting?. **2022**, 175-200 0

7 Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis. *Journal of Clinical Medicine*, **2022**, 11, 3717 5.1

6 Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. *Inflammopharmacology*, **2022**, 30, 1167-1178 5.1 0

5 Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. **2022**, 20, 1

4 Endocannabinoid System and the Otolaryngologist. **2022**, 0

3 Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases. 0

2 Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. **2023**, 74, 104711 0

1 Neurobiology of Cannabinoids and Medical Cannabis in Therapeutic Intervention for Multiple Sclerosis. **2023**, 187-216 0